INX-315, a CDK2 inhibitor, gained FDA fast track status in CCNE1-positive platinum-resistant/refractory ovarian cancer.

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

Olalekan O Oluwole, MD, MBBS, discussed a study on cytokine release syndrome and neurological events post axicabtagene ...

During a live event, Naresh Bumma, MD, discussed talquetamab’s efficacy in relapsed/refractory multiple myeloma, including high-risk patients.

Ravindra Uppaluri, MD, PhD, discussed the KEYNOTE-689 trial, which investigated pembrolizumab in locally advanced head and ...

Ramos, MD, PhD, discusses the importance of the findings from the SunRISe-1 study of TAR-200 in bladder cancer from the 2025 AUA Annual Meeting.

In interviews with Targeted Oncology, Ronan J. Kelly, MD, MBA, and David Zhen, MD, discuss the CheckMate 649 trial of ...

An expert discusses how addressing unmet needs in early diagnosis, treatment options, and long-term management, alongside ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84 ...

The key takeaways are that prostate cancer misinformation is widespread across online platforms and spans many different ...

An expert discusses how effective blastic plasmacytoid dendritic cell neoplasm (BPDCN) management requires early central nervous system (CNS) evaluation and a multidisciplinary approach, with ...